Holen Sie sich die Stockscreener-App
0.7247
6.39%
0.0435
Handel nachbörslich:
.75
0.0253
+3.49%
Schlusskurs vom Vortag:
$0.6812
Offen:
$0.767
24-Stunden-Volumen:
245.06K
Relative Volume:
0.05
Marktkapitalisierung:
$3.78M
Einnahmen:
$852.30K
Nettoeinkommen (Verlust:
$-21.37M
KGV:
-0.0334
EPS:
-21.6981
Netto-Cashflow:
$-19.06M
1W Leistung:
-4.63%
1M Leistung:
-39.10%
6M Leistung:
-72.44%
1J Leistung:
-96.00%
1-Tages-Spanne:
$0.68
$0.767
1-Wochen-Bereich:
$0.6388
$0.767
52-Wochen-Spanne:
$0.6388
$20.00
Geovax Labs Inc Stock (GOVX) Company Profile
Firmenname
Geovax Labs Inc
Sektor
Branche
Telefon
678-384-7220
Adresse
1955 LAKE PARK DRIVE, SMYRNA
Compare GOVX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
0.7247 | 3.96M | 852.30K | -21.37M | -19.06M | -21.70 |
VRTX
Vertex Pharmaceuticals Inc
|
470.72 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
759.24 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
830.79 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
182.45 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
313.77 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2025-04-15 | Bestätigt | Alliance Global Partners | Buy |
| 2025-04-15 | Bestätigt | D. Boral Capital | Buy |
| 2024-11-11 | Eingeleitet | Alliance Global Partners | Buy |
| 2024-07-16 | Eingeleitet | ROTH MKM | Buy |
| 2020-11-19 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Geovax Labs Inc Aktie (GOVX) Neueste Nachrichten
GeoVax Labs Inc (GOVX) Valuation: PE, PB & Fair Value Analysis - TradingKey
GeoVax Labs, Inc. 2026 Q2 Financial Report: Earnings, Losses & Key Financial Statements Overview - Minichart
GeoVax Advances GEO-MVA Pivotal Study Amid Strategic Reprioritization - citybuzz -
GeoVax Labs, Inc. Reports Q2 2026 Financial Results and Advances in Immuno-Oncology Programs - Minichart
GEOVAX LABS ($GOVX) Releases Q2 2026 Earnings - Quiver Quantitative
GeoVax Labs Inc reports results for the quarter ended June 30Earnings Summary - TradingView
GeoVax Reports Q2 2026 Net Loss of $4.4 Million - Quiver Quantitative
GeoVax Labs reports Q2 net loss $4.43M, cash ~$3.1M; advances GEO‑MVA pivotal study - TradingView
GeoVax Labs, Inc. 2026: Revenue $0 EPS ($0.97) — 10-Q Summary - TradingView
GeoVax Labs (GOVX) narrows loss but warns on cash runway and Nasdaq risk - Stock Titan
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update - TradingView
GeoVax Labs Inc (GOVX) Cash Flow - TradingKey
GeoVax Labs Inc (GOVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GeoVax Labs Inc (GOVX) Balance Sheet - TradingKey
GeoVax Labs Inc (GOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GeoVax Labs, Inc. Revenue Breakdown – NASDAQ:GOVX - TradingView
GOVX|GeoVax Labs Inc|Price:0.755|Chg%:+0.024 - TradingKey
GOVX|GeoVax Labs Inc|Price:0.731|Chg%:-0.109 - TradingKey
GeoVax Labs Inc (GOVX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GeoVax Labs Inc (GOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GeoVax Labs Inc (GOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GOVX|GeoVax Labs Inc|Price:0.733|Chg%:-0.107 - TradingKey
GeoVax Labs Inc expected to post a loss of $2.88 a shareEarnings Preview - TradingView
GeoVax Labs Inc (GOVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy - Yahoo Finance
GOVX stock soars 80%: Retail traders are piling in as Ebola, hantavirus risks resurface - MSN
GeoVax Labs(GOVX) Stock Options Chain | Quotes & News - Moomoo
Why Is GOVX Stock Falling Today? - Stocktwits
GeoVax Labs Faces Nasdaq Noncompliance and Listing Risk - The Globe and Mail
GOVX Stock Became A Hot Biodefense Trade Amid Ebola, Hantavirus Concerns - Stocktwits
GeoVax Labs, Inc. Receives Nasdaq Delisting Notice – Company Plans to Regain Compliance | 8-K Filing July 2026 - Minichart
GeoVax Labs Inc (GOVXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GEOVAX LABS INC (GOVX) Stock Chart - ChartMill
GeoVax Labs Received Notice of Noncompliance - TradingView
GeoVax Labs | 8-K: Current report - Moomoo
GeoVax Labs (NASDAQ: GOVX) flagged for Nasdaq $2.5M equity shortfall, delisting risk - Stock Titan
GeoVax Labs (GOVX) Stock Forecast & Analyst Ratings - Moomoo
GeoVax Labs Company Profile & Introduction - Moomoo
GOVX Should I Buy - Intellectia AI
Price to earnings forward of GeoVax Labs, Inc. – NASDAQ:GOVX - TradingView
GeoVax Highlights U.S. Government Investment in Orthopox Preparedness as Validation of Long-Term Vaccine Readiness - citybuzz -
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness - Yahoo Finance
GOVX Q1 2026 Earnings: Narrower-Than-Expected Loss Bolsters Investor SentimentProduct Revenue Analysis - dars.gov.et
GeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline Shift - Yahoo Finance
GeoVax Labs, Inc. Actuals & Estimates (NASDAQ:GOVX) - TradingView
Price to book forward of GeoVax Labs, Inc. – NASDAQ:GOVX - TradingView
GOVX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of GeoVax Labs, Inc. – NASDAQ:GOVX - TradingView
Price to sales forward of GeoVax Labs, Inc. – NASDAQ:GOVX - TradingView
Form 4 GeoVax Labs Inc For: 22 June By Investing.com - Investing.com Australia
GeoVax (GOVX) director receives 6,000 stock options at $1.18 strike - Stock Titan
Finanzdaten der Geovax Labs Inc-Aktie (GOVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):